MX394909B - Uso de la akkermansia pasteurizada para tratar trastornos metabolicos - Google Patents

Uso de la akkermansia pasteurizada para tratar trastornos metabolicos

Info

Publication number
MX394909B
MX394909B MX2018002990A MX2018002990A MX394909B MX 394909 B MX394909 B MX 394909B MX 2018002990 A MX2018002990 A MX 2018002990A MX 2018002990 A MX2018002990 A MX 2018002990A MX 394909 B MX394909 B MX 394909B
Authority
MX
Mexico
Prior art keywords
pasteurized akkermansia
metabolic disorders
treating metabolic
fragments
relates
Prior art date
Application number
MX2018002990A
Other languages
English (en)
Other versions
MX2018002990A (es
Inventor
Amandine Everard
Clara Belzer
Céline Druart
Hubert Plovier
Patrice Cani
Vos Willem De
Original Assignee
Univ Catholique Louvain
Univ Wageningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394909(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Catholique Louvain, Univ Wageningen filed Critical Univ Catholique Louvain
Publication of MX2018002990A publication Critical patent/MX2018002990A/es
Publication of MX394909B publication Critical patent/MX394909B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a Akkermansia muciniphila pasteurizada o a fragmentos de la misma para tratar un trastorno metabólico en un sujeto que lo necesita. La presente invención también se refiere a una composición, a una composición farmacéutica y a un medicamento que comprende la Akkermansia muciniphila pasteurizada o fragmentos de la misma para tratar un trastorno metabólico. La presente invención también se refiere al uso de Akkermansia muciniphila pasteurizada o fragmentos de la misma para promover la pérdida de peso en un sujeto que lo necesita.
MX2018002990A 2015-09-10 2016-09-09 Uso de la akkermansia pasteurizada para tratar trastornos metabolicos MX394909B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15184758 2015-09-10
PCT/EP2016/071327 WO2017042347A1 (en) 2015-09-10 2016-09-09 Use of pasteurized akkermansia for treating metabolic disorders

Publications (2)

Publication Number Publication Date
MX2018002990A MX2018002990A (es) 2018-06-08
MX394909B true MX394909B (es) 2025-03-24

Family

ID=54145609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002990A MX394909B (es) 2015-09-10 2016-09-09 Uso de la akkermansia pasteurizada para tratar trastornos metabolicos

Country Status (15)

Country Link
US (2) US10736924B2 (es)
EP (3) EP3626081B1 (es)
JP (2) JP6954563B2 (es)
KR (5) KR20230125340A (es)
CN (2) CN108289918B (es)
AU (2) AU2016319221B2 (es)
BR (1) BR112018004532B1 (es)
DK (2) DK3347030T3 (es)
EA (1) EA201800199A1 (es)
ES (3) ES3031514T3 (es)
IL (1) IL257978B (es)
MX (1) MX394909B (es)
PL (3) PL3626081T3 (es)
PT (2) PT3347030T (es)
WO (1) WO2017042347A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
PL3291679T3 (pl) 2015-05-06 2022-04-25 Snipr Technologies Limited Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
WO2016177797A1 (en) 2015-05-06 2016-11-10 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
ES3031514T3 (en) * 2015-09-10 2025-07-09 Univ Catholique Louvain Use of pasteurized akkermansia for treating cancer
PL3443071T3 (pl) * 2016-04-11 2022-03-28 Wageningen Universiteit Nowe gatunki bakterii
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
KR102212606B1 (ko) 2017-09-28 2021-02-05 주식회사 고바이오랩 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN113038957A (zh) 2018-04-10 2021-06-25 谢尔塔治疗公司 微生物群
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
KR102377407B1 (ko) * 2018-10-01 2022-03-22 한국생명공학연구원 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN109259240A (zh) * 2018-10-12 2019-01-25 人和未来生物科技（长沙）有限公司 调节肠道菌群和防治肥胖的组合物及其应用
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
FR3099054A1 (fr) * 2019-07-24 2021-01-29 Institut National De La Recherche Agronomique (Inra) Souche de Christensenella pour son utilisation dans le traitement et la prévention d’une inflammation gastro-intestinale
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
KR102128289B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
KR102128287B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
CN110679949A (zh) * 2019-09-30 2020-01-14 山东晶辉生物技术有限公司 一种减肥组合物及其制备方法
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
CN110786376A (zh) * 2019-11-07 2020-02-14 中南大学湘雅医院 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
CN115243695A (zh) * 2019-12-23 2022-10-25 潘德勒姆治疗公司 包含微生物的组合物及其使用方法和制备方法
WO2021203083A2 (en) * 2020-04-02 2021-10-07 Dupont Nutrition Biosciences Aps Compositions for metabolic health
US20230173019A1 (en) 2020-04-24 2023-06-08 Kobiolabs, Inc. Protein Variant Having GLP-1 Inducing Activity and Use Thereof
KR102309911B1 (ko) * 2020-05-11 2021-10-07 재단법인 아산사회복지재단 신규한 아커만시아 뮤시니필라 ak32 균주의 발견 및 장 손상의 예방 또는 치료를 위한 응용
KR102185827B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028330B1 (fr) * 2020-11-09 2021-12-17 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de camu camu
BE1028339B1 (fr) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113041214A (zh) * 2021-03-16 2021-06-29 中南大学湘雅医院 一种负载嗜粘蛋白-艾克曼菌的改性透明质酸水凝胶及其制备方法和应用
CN113116936A (zh) * 2021-04-02 2021-07-16 上海市第六人民医院 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113265359A (zh) * 2021-05-26 2021-08-17 广西壮族自治区兽医研究所 一种改良的嗜黏蛋白阿克曼氏菌液体培养方法
BE1029502B1 (fr) * 2021-08-19 2023-01-17 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention de l'anxiété liée au syndrome du côlon irritable
BE1029496B1 (fr) 2021-08-19 2023-01-16 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale
FR3129831B1 (fr) 2021-12-07 2025-04-11 Activinside Utilisation d’une composition à base de Crocus sativus comme prébiotique
WO2023121955A1 (en) * 2021-12-20 2023-06-29 Tainnovation Inc. The methods of and compositions for treating obesity, obesity-related diseases or cancers using a n6-methyllysine/l-lysine mixture
CN114949003B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌及其应用和培养方法
CN114949002B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN115612635B (zh) * 2022-06-23 2024-08-27 济南大学 一种嗜黏蛋白艾克曼菌ww001及其组合物、复合菌剂与应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN115777625A (zh) * 2022-10-17 2023-03-14 复旦大学 一种建立帕金森病动物模型的方法
CN116925975B (zh) * 2023-08-18 2024-01-23 善恩康生物科技（苏州）有限公司 一种Akkermansia muciniphila及其产品和应用
CN116999468B (zh) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
CN117482128A (zh) * 2023-09-18 2024-02-02 南京北极光生物科技有限公司 一种含嗜黏蛋白阿克曼菌后生元的组合物及其在糖代谢脂代谢中的应用
CN118178476A (zh) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1931363B1 (en) * 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
JP2012524910A (ja) 2009-04-23 2012-10-18 カリフォルニア インスティチュート オブ テクノロジー 免疫調節物質の同定方法及びシステム
EP2251020A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP2524029B1 (en) * 2010-01-15 2018-03-21 The Regents of The University of California Electro-autotrophic synthesis of higher alcohols
EP2449891A1 (en) * 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
ES2565407T3 (es) * 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
AU2011328041A1 (en) * 2010-11-11 2013-05-23 Nestec S.A. Spoonable yogurt preparations containing non-replicating probiotic micro-organisms
JP5813976B2 (ja) * 2011-03-29 2015-11-17 ユニ・チャーム株式会社 ペット用おむつ
US20140171339A1 (en) * 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
KR20130021920A (ko) 2011-08-24 2013-03-06 포항공과대학교 산학협력단 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 또는 Ｂａｃｔｅｒｏｉｄｅｓ ａｃｉｄｉｆａｃｉｅｎｓ 유래 세포밖 소포체를 유효성분으로 함유하는 염증성 질환의 치료 또는 예방용 조성물
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
WO2014007606A1 (en) * 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
CN104540962B (zh) * 2012-08-01 2017-09-19 深圳华大基因研究院 糖尿病生物标志物及其应用
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
WO2016172657A2 (en) * 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
WO2016177797A1 (en) * 2015-05-06 2016-11-10 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
ES3031514T3 (en) * 2015-09-10 2025-07-09 Univ Catholique Louvain Use of pasteurized akkermansia for treating cancer
WO2017060698A1 (en) * 2015-10-05 2017-04-13 Liam O'mahony Use of akkermansia muciniphila for treating inflammatory conditions
CN115996943A (zh) * 2020-07-01 2023-04-21 瓦赫宁根大学 用于影响免疫信号传导和/或影响肠屏障功能和/或调节代谢状态的Amuc-1100多肽变体
CN113862193B (zh) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
EP3347030A1 (en) 2018-07-18
DK3626081T3 (da) 2022-02-28
AU2022203731A1 (en) 2022-06-23
ES2908310T3 (es) 2022-04-28
EP3943093B1 (en) 2025-05-07
PL3626081T3 (pl) 2022-04-25
KR20230070053A (ko) 2023-05-19
PL3347030T3 (pl) 2021-11-22
DK3347030T3 (da) 2021-08-09
KR102569754B1 (ko) 2023-08-23
KR102581908B1 (ko) 2023-09-22
PT3347030T (pt) 2021-08-19
AU2016319221B2 (en) 2022-06-30
PT3626081T (pt) 2022-02-25
AU2016319221A1 (en) 2018-03-29
EP3626081A1 (en) 2020-03-25
JP2019500004A (ja) 2019-01-10
ES3031514T3 (en) 2025-07-09
HK1257222A1 (en) 2019-10-18
KR20240137695A (ko) 2024-09-20
BR112018004532B1 (pt) 2022-03-15
PL3943093T3 (pl) 2025-09-01
EA201800199A1 (ru) 2018-12-28
ES2883231T3 (es) 2021-12-07
JP2022000040A (ja) 2022-01-04
MX2018002990A (es) 2018-06-08
KR20230125340A (ko) 2023-08-29
US20180250347A1 (en) 2018-09-06
EP3626081B1 (en) 2022-02-09
IL257978B (en) 2021-12-01
KR20220148941A (ko) 2022-11-07
KR20180053336A (ko) 2018-05-21
CN108289918B (zh) 2022-01-18
BR112018004532A2 (pt) 2018-12-11
WO2017042347A1 (en) 2017-03-16
IL257978A (en) 2018-05-31
JP6954563B2 (ja) 2021-10-27
KR102530852B1 (ko) 2023-05-12
CA2998039A1 (en) 2017-03-16
AU2022203731B2 (en) 2025-02-27
CN108289918A (zh) 2018-07-17
US20210015876A1 (en) 2021-01-21
EP3347030B1 (en) 2021-07-14
EP3943093C0 (en) 2025-05-07
CN114276960A (zh) 2022-04-05
US10736924B2 (en) 2020-08-11
EP3943093A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MY187540A (en) Compounds active towards bromodomains
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MD20170020A2 (ro) Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
MX2018006223A (es) Moduladores de ror-gamma.
GB2541571A (en) Pharmaceutical compositions
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
ZA202503388B (en) Semaglutide in medical therapy
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
IN2013MU03429A (es)
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.